 2. To establish whether there is a clinical response to vitamin D measured by a change in the number of T2 lesions and Gadolinium enhancing lesions on MRI scanning at 24 weeks compared to baseline b reduction in relapses over 24 weeks in treated both 5,000 IU and 10,000 IU CIS patients versus CIS patients receiving placebo. 